DESLORATADINE ALLERGY CONTROL TABLET

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

DESLORATADINE

Доступна с:

DOMINION PHARMACAL

код АТС:

R06AX27

ИНН (Международная Имя):

DESLORATADINE

дозировка:

5MG

Фармацевтическая форма:

TABLET

состав:

DESLORATADINE 5MG

Администрация маршрут:

ORAL

Штук в упаковке:

10/20/30/50/70

Тип рецепта:

OTC

Терапевтические области:

SECOND GENERATION ANTIHISTAMINES

Обзор продуктов:

Active ingredient group (AIG) number: 0143961001; AHFS:

Статус Авторизация:

CANCELLED POST MARKET

Дата Авторизация:

2020-05-06

Характеристики продукта

PRODUCT MONOGRAPH
DESLORATADINE ALLERGY CONTROL
Desloratadine tablets
5 mg
Histamine H
1
-Receptor Antagonist
DOMINION PHARMAC
A
L
6111 Royalmount Avenue, Suite 100
Montreal, Quebec
H4P 2T4
Date of Preparation:
July 10, 2017
Submission Control No.: 206132
_DESLORATADINE ALLERGY CONTROL _
_Page 2 of 36_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................5
DRUG INTERACTIONS
....................................................................................................6
DOSAGE AND ADMINISTRATION
................................................................................7
OVERDOSAGE
..................................................................................................................8
ACTION AND CLINICAL PHARMACOLOGY
..............................................................8
STORAGE AND STABILITY
..........................................................................................11
SPECIAL HANDLING INSTRUCTIONS
.......................................................................11
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................11
PART II: SCIENTIFIC INFORMATION
...............................................................................12
PHARMACEUTICAL INFORMATION
..........................................................................12
CLINICAL TRIALS
...........................................................................